{
    "clinical_study": {
        "@rank": "84116", 
        "acronym": "MOBILE", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "ASP8477", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the painkilling efficacy of ASP8477 relative to mock\n      (placebo) in patients that have been diagnosed with painful diabetic peripheral neuropathy\n      or postherpetic neuralgia determined by the change in the average daily pain intensity in\n      patients that initially respond favorably to treatment with ASP8477."
        }, 
        "brief_title": "A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuropathic Pain", 
            "Painful Diabetic Peripheral Neuropathy (PDPN)", 
            "Post-Herpetic Neuralgia (PHN)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Pain", 
                "Peripheral Nervous System Diseases", 
                "Neuralgia, Postherpetic", 
                "Diabetic Neuropathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will consist of a Screening Period, Single-Blind Treatment Period, Double-Blind\n      Randomized Withdrawal Period and Follow-up Period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  PDPN subject must have:\n\n               -  Established diagnosis of diabetes (type I or II) with painful diabetic\n                  peripheral neuropathy and glycosylated hemoglobin (HbA1c) \u2264 11% at Screening.\n\n               -  Stable glycemic control (HbA1c \u2264 11%) achieved by a drug regimen for at least 3\n                  months prior to Screening.\n\n               -  At least a 1-year history of DPN pain.\n\n               -  Diabetic distal symmetrical polyneuropathy symptoms (including pain) stable for\n                  at least the last 3 months prior to Screening based on PI judgment and\n                  subject-reported medical history.\n\n          -  PHN subject must have pain present \u2265 6 months after healing of the herpes zoster\n             rash.\n\n        Exclusion Criteria:\n\n          -  Subject has significant pain of an etiology other than PDPN or PHN, or clearly non\n             differentiated pain, or plantar fasciitis, heel spurs, tibial neuropathy, Morton's\n             neuroma, bunions, metararsalgia, arthritis in feet, ischemic pain, neurological\n             disorders unrelated to diabetic neuropathy, skin condition in area of neuropathy\n             that could alter sensation, malignancy, or current orthostatic hypotension, hypo or\n             hypertension, syncope or clinically significant ECG, clinical intolerance  to\n             Non-steroidal anti-inflammatory drugs (NSAIDs) or ASP8477, depression, psychosis or\n             psychiatric or neurological illness, BMI of over 35, renal impairment or failure,\n             alcohol (ETOH) or drug abuse, GI complaints.\n\n          -  Previous investigational therapy within 28 days or 5 half lives"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065349", 
            "org_study_id": "8477-CL-0020", 
            "secondary_id": "2013-002521-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP8477", 
                "description": "oral", 
                "intervention_name": "ASP8477", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "peripheral neuropathy", 
            "PDPN", 
            "PHN", 
            "pain"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Warszawa", 
                    "country": "Poland", 
                    "zip": "00-465"
                }, 
                "name": "Site: PL48005"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Global Clinical Science, APGD", 
            "phone": "+31 (0)71 5455 050"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in mean of 24-hour average pain intensity, Numeric pain rating scale (NPRS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline of the double-blind randomized withdrawal period to the last 3 days of double-blind randomized withdrawal period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065349"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Treatment failure is defined as mean 24 hour pain intensity was equal or more than 4 with at least a 30% increase in pain intensity relative to baseline of the double-blind randomized withdrawal period", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Date of randomization to first 3 consecutive days of double-blind period with an observed treatment failure"
            }, 
            {
                "measure": "Responder rate to ASP8477 in the Single-Blind Period", 
                "safety_issue": "No", 
                "time_frame": "Baseline of the single-blind period (last 3 days of the placebo run-in period) to baseline of the double-blind period (last 3 days of the single-blind period"
            }, 
            {
                "measure": "Patient Global Impression of Change (PGIC) score", 
                "safety_issue": "No", 
                "time_frame": "From the baseline of the single-blind period to End of Treatment Visit (Day 49 or upon early discontinuation)"
            }, 
            {
                "description": "TEAE=Treatment Emergent Adverse Events, SAE = Serious Adverse Event, C-SSRS = Columbia Suicide Severity Rating Scale, PWC = Physician Withdrawal Checklist, MWC = Marijuana Withdrawal Checklist", 
                "measure": "Safety assessed by TEAE and SAE, laboratory tests, vital signs, C-SSRS, PWC and MWC scores, Bond-Lader score", 
                "safety_issue": "No", 
                "time_frame": "From Screening to End of Study Visit (13 weeks)"
            }, 
            {
                "measure": "Composite of pharmacokinetics of ASP8477 concentration: Trough concentration (Ctrough), observed maximum concentration (Cmax), Area under the curve (AUC)0-6", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}